This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, T. Articles by Nakagawa, M. Search for Related Content PubMed PubMed Citation Articles by Nakamura, T. Articles by Nakagawa, M. Related Collections Biochemistry and metabolism

(Hypertension. 2000;36:215.)
© 2000 American Heart Association, Inc.

Scientific Contributions

Can Serum Carnitine Levels Distinguish Hypertrophic Cardiomyopathy From Hypertensive Hearts?

Tomoki Nakamura; Hiroki Sugihara; Noriyuki Kinoshita; Satoshi Yoneyama; Akihiro Azuma; Masao Nakagawa

From the Second Departments of Medicine (T.N., N.K., S.Y., A.A., M.N.) and Radiology (H.S.), Kyoto Prefectural University of Medicine, Kyoto, Japan.

Correspondence to Tomoki Nakamura, MD, Second Department of Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto 602-0841, Japan.

Abstract—Although echocardiography is a useful diagnostic tool in hypertrophic cardiomyopathy (HCM), it is sometimes difficult to differentiate it from hypertensive heart disease (HHD): some patients with HCM show symmetrical hypertrophy, whereas patients with HHD sometimes show asymmetrical septal hypertrophy. We used a radioiodinated long-chain fatty acid tracer to visualize the altered myocardial fatty acid metabolism of HCM and HHD. Carnitine is the essential substance for the ß-oxidation of long-chain fatty acids. We recently reported that serum free carnitine levels in HCM were elevated and that they were significantly correlated with the severity of myocardial fatty acid metabolic disorder. Therefore, we investigated serum carnitine levels in patients with HCM and HHD, which can contribute to the differentiation of each other. We studied 56 patients with HCM and 20 patients with essential hypertension. Serum free carnitine levels were significantly higher in patients with HCM than those with HHD (HCM 52.5±9.5 nmol/mL, HHD 46.6±6.4 nmol/mL, P<0.01), but they showed no statistical difference between patients with HHD and normal subjects. Serum acylcarnitine levels were significantly lower in patients with HCM than those with HHD (HCM 10.1±4.0 nmol/mL, HHD 14.5±4.9 nmol/mL, P<0.0005), although they did not differ between patients with HHD and normal subjects. Scintigraphic analyses with a long-chain fatty acid analog revealed that myocardial tracer uptake was much reduced in patients with HCM compared with that in patients with HHD (quantitative analysis: HCM 2.11±0.12, HHD 2.22±0.17, P<0.05; semiquantitative analysis: HCM 13.6±6.3, HHD 2.0±1.5, P<0.0001). In conclusion, the differences in serum carnitine levels between HCM and HHD reflect altered myocardial fatty acid metabolic impairment, and the levels can help to distinguish these 2 diseases.

Key Words: fatty acids • hypertrophy, cardiac • cardiomyopathy • metabolism

This article has been cited by other articles:

				T. S. Kato, A. Noda, H. Izawa, A. Yamada, K. Obata, K. Nagata, M. Iwase, T. Murohara, and M. Yokota Discrimination of Nonobstructive Hypertrophic Cardiomyopathy From Hypertensive Left Ventricular Hypertrophy on the Basis of Strain Rate Imaging by Tissue Doppler Ultrasonography Circulation, December 21, 2004; 110(25): 3808 - 3814. [Abstract] [Full Text] [PDF]